Crossmark

A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study

Crossref DOI link: https://doi.org/10.1007/s00216-019-02184-4

Published Online: 2019-11-16

Published Print: 2019-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Parker, Suzanne L.

Pandey, Saurabh

Sime, Fekade B.

Lipman, Jeffrey

Roberts, Jason A.

Wallis, Steven C.
Funding

Funding for this research was provided by:

Melinta Therapeutics, USA (NA)
License Information

Text and Data Mining valid from 2019-11-01

Version of Record valid from 2019-11-01
More Information

Article History

Received: 28 July 2019

Revised: 12 September 2019

Accepted: 1 October 2019

First Online: 16 November 2019

Compliance with ethical standards

: The study was performed in accordance with the ethical standards, with ethical approval obtained for the use of drug-free human blood from the Royal Brisbane & Women’s Hospital Human Research Ethics Committee HREC/15/QRBW/249.

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below